In the Margins
Hedge-fund billionaire John Paulson has joined the Valeant Pharmaceuticals International board of directors. Paulson has been one of the largest shareholders in the company for several years, but a series of scandals at Valeant over its accounting practices and drug pricing have battered the company’s stock and caused the value of Paulson’s stake to plunge 81% to $245 million at the end of last year from $1.3 billion in 2015. Read the original story from The Wall Street Journal.
Most Read
A conversation with Sidley Austin's Nathan Greene, BlackRock's Dr. Rachel Schutt, and FundGuard's Lior Yogev: What is artificial intelligence, and how much do mutual fund industry ...
The Securities and Exchange Commission this week finalized its rule on funds' use of derivatives, making some notable changes to what was proposed nearly a year ...
If Allan Reich thought he was going to sail smoothly through his 27th and final year on the board of Oakmark Funds, he was mistaken. Reich ...
Resignations, retirements and recruitment over the past five years have led to significant changes in the Sequoia Fund boardroom. The transformation was set in motion in ...